全球子宮內膜異位症藥物市場規模（按產品、應用、地區、範圍和預測）

Global Endometriosis Drugs Market Size By Product(Hormonal Therapy, Add-back Medication, Progestogens), By Application(Hospitals, Clinics, Research Institutes), By Geographic Scope And Forecast

出版日期: 2024年08月15日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

子宮內膜異位症藥物市場規模及預測

近年來子宮內膜異位症藥物的市場規模一直以顯著的速度快速增長，預計2021年至2028年的市場規模、估計和預測中該市場將出現大幅增長。

子宮內膜異位症盛行率的不斷上升也提高了女性對子宮內膜異位症治療的認識。此外，子宮內膜異位症發生率的顯著增加和研發投入也為該市場創造了進一步的成長機會。全球子宮內膜異位症藥物市場報告對市場進行了全面的評估。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

全球子宮內膜異位症藥物市場的定義

子宮內膜異位症是一種慢性、疼痛的疾病，其中子宮周圍的組織（存在於輸卵管、卵巢和支撐子宮的韌帶中）破裂，引起發炎和內出血。這會導致不孕、沾黏、疼痛、疤痕組織形成和腸道問題。此病的症狀包括月經期間排便疼痛，性交疼痛，月經前和月經期間疼痛，不孕，月經期間排尿疼痛，疲勞以及腹瀉，噁心和便秘等胃腸道問題。由於子宮內膜異位症是一種終身疾病，因此根據疾病的程度、疼痛程度和生育能力製定醫療管理策略非常重要。

多種藥物可用於治療子宮內膜異位症，包括止痛藥、荷爾蒙避孕藥、僅含孕酮的避孕藥、促性腺激素釋放激素 (GnRH) 類似物和芳香酶抑制劑。芳香化酶是一種能增加體內雌激素產生的化學物質。芳香化酶抑制劑可以阻止這一過程，從而降低雌激素水平。這些藥物不常規用於治療子宮內膜異位症。另一方面，荷爾蒙避孕藥可以阻止通常伴隨子宮內膜異位症出現的月經過多。

全球子宮內膜異位症藥物市場概況

對女性健康日益增長的興趣是預測期內推動子宮內膜異位症藥物市場規模成長的關鍵因素。各政府部門和組織正在努力提高人們的意識，以克服無知和缺乏教育帶來的課題。對女性健康的關注將導致全球子宮內膜異位症藥物市場的擴大。此外，該疾病的發生率正在顯著增加，預計研發投資將積極推動全球子宮內膜異位症藥物市場的成長。

市場面臨某些限制和課題，阻礙了整體成長。例如，子宮內膜異位症藥物市場以高成本的荷爾蒙治療為主，這是患者主要關心的問題，預計在預測期內將減緩市場成長。此外，對於子宮內膜異位症和子宮內膜癌等各種婦科癌症適應症的認知不足，對市場成長構成了課題。此外，診斷該疾病所需的時間很長，研究人員估計需要七到九年。目前，由於缺乏醫療基礎設施和高科技醫療設備和器械，無法進行非侵入性診斷測試。這些都是阻礙全球子宮內膜異位症藥物市場整體成長的潛在因素。

The growing prevalence of endometriosis has also lead to higher awareness among women related to endometriosis treatment. Moreover, the significant rise in the occurrence of this disease, investment in research, and development are also increasingly expanding growth opportunities in this market. The Global Endometriosis Drugs Market report provides a holistic evaluation of the market. The report offers comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Endometriosis Drugs Market Definition

Endometriosis is a chronic and painful condition, where the tissues that outline the uterus externally (found in the fallopian tubes, ovaries, and ligaments that support the uterus) ruptures and causes inflammation and internal bleeding. This can cause infertility, adhesions, pain, scar tissue formation, and bowel problems. Symptoms of the disease include painful bowel movements during periods, pain with sex, pain before and during periods, infertility, painful urination during periods, fatigue, and other gastrointestinal problems such as diarrhea, nausea, and constipation. Endometriosis is a lifelong condition so it is important to develop a medical strategy to manage it based on the extent of the disease, severity of pain, and potential plans for pregnancy.

There are various medications available to cure endometriosis such as Pain Medication, Hormone Birth Control, Progestin-only contraceptives, Gonadotroin-releasing Hormone (GnRH) Analogues, and Aromatase Inhibitors. Aromatase is a chemical that boosts your body's estrogen production. Aromatase inhibitors block it, which lowers your estrogen level. These medicines aren't routinely used to treat endometriosis. Whereas, hormone birth control can stop the heavy menstrual bleeding that generally accompanies endometriosis.

Global Endometriosis Drugs Market Overview

The growing focus emphasis on women's health is the key factor in boosting the growth of the endometriosis drugs market size during the forecast period. The various governmental authorities and organizations are working to raise awareness to overcome unawareness and uneducated challenges problems. The focus on women's health will lead to the expansion of the global endometriosis drugs market. Moreover, the significant rise in the occurrence of this disease, investment in research, and development has positively anticipated in propelling the growth of the global Endometriosis drugs market.

There are certain restraints and challenges faced which will hinder the overall market growth. The factors such as the endometriosis drug market are dominated by high-cost hormone-based therapeutics, which is a significant concern for patients and is estimated to sluggish growth during the forecast period. Lack of awareness about various gynecological cancer indications such as endometriosis and endometrial cancer was a challenge for the growth of the market. Further, the time that is taken to diagnose the disease is high, which is estimated by the researchers as seven to nine years. Till now, there are no diagnostic tests available that are non-invasive coupled with a lack of medical infrastructure and hi-tech medical equipment and devices. These are the potential restraints hampering the overall growth of the global Endometriosis drugs market.

Global Endometriosis Drugs Market: Segmentation Analysis

Global Endometriosis Drugs Market is segmented based on Product, Application, And Geography.

Endometriosis Drugs Market by Product

Hormonal Therapy
Add-back Medication
Progestogens
Chinese Herbs

Based on Product, the market is bifurcated into Hormonal Therapy, Add-back Medication, Progestogens, and Chinese Herbs. The hormone therapy segment holds the largest market share for the forecast period. It is considered the most effective treatment for endometriosis as it can reduce or effectively eliminate the pain associated with the condition compared with analgesics. This factor will increase sales of medications that act on hormones associated with the condition. The sales of hormonal medications will further improve with the introduction of novel drug delivery systems.

Endometriosis Drugs Market by Application

Hospitals
Clinics
Research Institutes

Based on Application, the market is bifurcated into Hospitals, Clinics, Research Institutes. The hospital segment is estimated to witness the highest CAGR for the forecast period. The factors that can be attributed to the growing prevalence of endometriosis and rise in the occurrence of this disease are fueling the demand for this segment.

Endometriosis Drugs Market by Geography

On the basis of regional analysis, the Global Endometriosis Drugs Market is classified into

North America

Europe

Asia Pacific

Rest of the world

North America holds the largest market share. The increasing treatment costs, higher disability losses, and the large number of reproductive populations that are suffering from endometriosis. High awareness among people, strong governmental initiatives and ongoing projects will boost the market in this region.

Key Players

The market analysis entails a section solely dedicated to major players in the Global Endometriosis Drugs Market wherein our analysts provide an insight into the financial statements of all the major players along with its key developments product benchmarking and SWOT analysis. The company profile section also includes a business overview and financial information. The companies that are provided in this section can be customized according to the client's requirements.

AbbVie
Astellas Pharma
AstraZeneca
Debiopharm Group
Evotec AG
Kissei Pharmaceutical
Neurocrine Biosciences
ObsEva
Pfizer
Repros Therapeutics
Roivant Sciences GmbH
Takeda Pharmaceutical Company Limited
ValiRx

Key Developments

Partnerships, Collaborations and Agreements

The US Food and Medication Administration (FDA) granted AbbVie Inc. approval for their drug ORILISS in July 2018. (elagolix). This is a GnRH-type medication that is used to relieve endometriosis pain that is severe to moderate.
In July 2017, Evotec AG reported that a programme from their multi-target endometriosis alliance with Bayer had moved into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
In January 2021, Myovant Sciences and Pfizer Inc. announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis found clinically significant reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over a year.

Product Launches and Product Expansions

In October 2018, Astellas Pharma Inc. reported that building and remodelling of new facilities for the research, development, and manufacture of novel pharmaceuticals employing new Modality/Technology had commenced in Toyama and Tsukuba, Japan, as well as Massachusetts, USA.